Solid tumors are characterized by a remodeled and stiffened extracellular matrix. The extracellular matrix is not a passive by-product of the tumor, but actively compromises tissue-specific differentiation, enhances tumor cell proliferation and survival, and fosters tumor cell invasion and migration. The tumor extracellular matrix also influences the behavior of the stromal cells, which through vicious, feedforward-reinforcing pathways promote tumor progression and compromise treatment efficacy. To investigate how the tumor extracellular matrix alters cancer phenotype and treatment, a number of three-dimensional, organotypic culture models have been developed that employ a variety of materials, including natural matrices, collagen, fibrin, and reconstituted basement membrane gels, as well as synthetic hydrogel materials such as polyacrylamide and polyethylene glycol. These models have been used to interrogate how specific microenvironmental features modify tumor and stromal cell function and to identify the molecular mechanisms that regulate tumorigenesis and therapeutic efficacy. To translate these findings into more effective treatment strategies for patients, clinically informed studies are needed that incorporate computational modeling and in vivo validation.
Triple-negative breast cancers (TNBCs) are associated with poor survival mediated by treatment resistance. TNBCs are fibrotic, yet little is known regarding how the extracellular matrix (ECM) evolves following therapy and whether it impacts treatment response. Analysis revealed that while primary untreated TNBCs are surrounded by a rigid stromal microenvironment, chemotherapy-resistant residual tumors inhabit a softer niche. TNBC organoid cultures and xenograft studies showed that organoids interacting with soft ECM exhibit striking resistance to chemotherapy, ionizing radiation, and death receptor ligand TRAIL. A stiff ECM enhanced proapoptotic JNK activity to sensitize cells to treatment, whereas a soft ECM promoted treatment resistance by elevating NF-κB activity and compromising JNK activity. Treatment-resistant residual TNBCs residing within soft stroma had elevated activated NF-κB levels, and disengaging NF-κB activity sensitized tumors in a soft matrix to therapy. Thus, the biophysical properties of the ECM modify treatment response, and agents that modulate stiffness-dependent NF-κB or JNK activity could enhance therapeutic efficacy in patients with TNBC.
Collagen deposition and stromal stiffening accompany malignancy, compromise treatment, and promote tumor aggression. Clarifying the molecular nature of and the factors that regulate extracellular matrix stiffening in tumors should identify biomarkers to stratify patients for therapy and therapeutic interventions to improve outcome. We profiled lysyl hydroxylase- and lysyl oxidase-mediated collagen crosslinks and quantified the greatest abundance of total and complex collagen crosslinks in more aggressive human breast cancer subtypes with the stiffest stroma. These tissues also harbored the highest number of tumor-associated macrophages (TAM), whose therapeutic ablation not only reduced metastasis, but also concomitantly decreased accumulation of collagen crosslinks and stromal stiffening. Epithelial-targeted expression of the crosslinking enzyme lysyl oxidase had no impact on collagen crosslinking in PyMT mammary tumors, whereas stromal cell targeting did. Consistently, stromal cells in microdissected human tumors expressed the highest level of collagen crosslinking enzymes. Immunohistochemical analysis of a cohort of breast cancer patient biopsies revealed that stromal expression of lysyl hydroxylase two, an enzyme that induces hydroxylysine aldehyde-derived collagen crosslinks and stromal stiffening correlated significantly disease specific mortality. The findings link tissue inflammation, stromal cell-mediated collagen crosslinking and stiffening to tumor aggression and identify lysyl hydroxylase two as a novel stromal biomarker. Significance: We show infiltrating macrophages induce stromal fibroblast, and not epithelial, expression of collagen crosslinking enzymes that drive tumor stiffening. Stromal enzyme LH2 is significantly upregulated in breast cancer patients with the stiffest stroma, the most trivalent HLCCs and the worst prognosis, underscoring its potential as a biomarker and therapeutic target.
There is an urgent need to better understand the cellular mechanisms driving liver fibrosis and to develop effective therapeutics. Hyaluronan is emerging as an important player in many fibrotic indications, and this is a very nice study investigating the role of hyaluronan in hepatic stellate cell (HSC) activation and liver fibrosis. The authors show that TGFb1 signaling through WT1 induces Has2 transcription in HSCs to increase production of hyaluronan in liver fibrosis. Using in vivo models of liver fibrosis and several in vivo and in vitro genetic manipulations, the authors convincingly demonstrate that increased HSC-derived hyaluronan from HAS2 binds CD44 on HSCs, which directly increases Notch1 transcription. They further show Notch1 is necessary for the profibrotic effect of HAS2. Finally, the authors demonstrate a potential for clinical translation of these findings by showing treatment with an inhibitor of hyaluronan synthesis reduces fibrosis in mouse models.
In this clever proof-of-concept preclinical study, the authors take advantage of the regenerative Wnt-boosting activity of R-spondins and target it to liver for the treatment of liver disease. R-spondins signal in many tissues, and specificity is critical for delivery as a therapeutic for liver disease. They engineered liver specificity into R-spondin in two ways. First, they modify the R-spondins to a peptide containing only the ZNRF/RNF binding domain through truncation and mutation of the LGR-binding motif. Second, they fused this protein to a liver-specific scFv or antibody. In vivo injections of liver-targeting peptide into mice revealed proliferation and upregulation of Wnt signaling comparable to wildtype R-spondin exclusively in liver whereas the peptide fused to a nontargeting antibody showed no activity. Full length R-spondin2 stimulated Wnt signaling in both liver and small intestine. The liver-targeting peptide may also expedite resolution of liver fibrosis in a chemically induced murine cirrhosis model; however, the extent to which this formulation can heal fibrosis isn’t fully tested. This report is an interesting demonstration of a strategy to target therapeutic peptides to liver that seems likely to be generalizable to other tissues and worthy of further investigation.